Advertisement

Topics

Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

18:08 EST 14th February 2016 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 17,000+

Extremely Relevant

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer


Add panitumumab or bevacizumab to improve first-line metastatic colorectal cancer therapy?

Dr Rivera talks to ecancertv at ECC 2015 about the final analysis of the PEAK randomized phase II study in patients with metastatic colorectal cancer and ways of improving upon current therapy. The primary endpoint was progression-free survival, which...

Cyramza indication extended

The indication of Cyramza (ramucirumab; Eli Lilly), in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), has been extended to include the treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. In addition, Cyramza in combination with docetaxel is also indicated ...


Colorectal cancer more likely to affect minorities at younger age

(University of Missouri-Columbia) Colorectal cancer is the third most common form of cancer and the second most common cause of cancer deaths in the United States. The chance of developing colorectal cancer increases with age. Now, a study by University of Missouri School of Medicine researchers shows that minority and ethnic groups are being diagnosed with colorectal cancer at younger ages and mo...

Lonsurf® Approved for the Treatment of Colorectal Cancer

The United States Food and Drug Administration (FDA) has approved the oral agent, Lonsurf® (trifluridine and tipiracil), for the treatment of colorectal cancer. Colorectal cancer remains the second leading cause of cancer-related deaths in the U.S. although death rates from colorectal cancer have declined in the past 10 years which is thought to be due […] The post Lonsurf® Approved for th...

Colorectal Cancer: Year in Review

After several years of exciting developments in colorectal cancer research and therapy, progress continued throughout 2015. The FDA approved a new drug to treat colorectal cancer, and much research has been done with combination therapies and protocols for treatment. Of great importance, research shows that when colorectal cancer is detected during a screening colonoscopy, patients […] The p...

New potential treatment for colorectal cancer discovered

A small molecule drug combined with chemotherapy may deliver a synergistic benefit for colorectal cancer patients, new research suggests. has demonstrated the efficiency of a small molecule drug, PRIMA-1met, in inhibiting the growth of colorectal cancer cells. Colorectal cancer is the cancer of the large intestine (colon and rectum).

Colorectal cancer: An intravenous probe for colorectal cancer screening

Early detection of colorectal lesions is the cornerstone of cancer prevention. Intravenous administration of a novel fluorescent peptide probe now enables the screening of the whole colorectal area using near-infrared fluorescence colonoscopy, an approach that was documented as safe, well-tolerated and specific in its detection of colorectal polyps.

Relevant

[Comment] Equal access to colorectal cancer screening

Population-based screening is effective in reducing the burden of colorectal cancer, and organised screening programmes have been implemented in many European countries.1 Maximum participation in screening is crucial to achieve the greatest health benefits at population level. As with most cancer screening programmes, however, there is a gradient in uptake of colorectal cancer screening by socioec...

Merck’s Erbitux approved for NHS Wales

The All Wales Medicines Strategy Group has recommended Merck’s Erbitux in combination with chemotherapy for restricted use in the NHS in Wales. Erbitux (cetuximab) is recommended for the first-line treatment of patients with RAS wild-type metastatic colorectal cancer. Its full indication is with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in com...

Colorectal cancer stemness and ERK

Colorectal cancer stemness and ERK Larry H. Bernstein, MD, FCAP, Curator LPBI   KCTD12 Regulates Colorectal Cancer Cell Stemness through the ERK Pathway Liping Li, Tingmei Duan, Xin Wang, Ru-Hua Zhang, Meifang Zhang, Suihai Wang,Fen Wang, Yuanzhong Wu, Haojie Huang & Tiebang Kang Scientific Reports 2016; 6(20460)    http://dx.doi.org:/10.1038/srep20460 Targeting cancer stem cells (CSC...

Effects of aspirin on colorectal cancer

In this interview Dr Din, a Cancer Research UK Clinician Scientist and Honorary Consultant Colorectal Surgeon, discusses her work looking at the use of aspirin as a chemopreventative agent in colorectal cancer (CRC) at the 2015 Scientific Conference of...

Recent Increase in Colorectal Cancer

The Fall 2015 issue of Cancer Today, a publication of the American Association for Cancer Research (AACR), features "Colorectal Cancer: A Troubling Trend."  Colorectal cancer diagnoses are on the rise among adults under age 50, lower than the recommended age to begin regular screening. Published quarterly by the AACR, Cancer Today is an authoritative resource for cancer patients, survivors, ...

Cancer-Suppressing Gene May Cause Colorectal Cancer Spread

University of Missouri School of Medicine researchers discovered that a cancer-suppressing gene called Sprouty2 may induce the growth of certain forms of colorectal cancer. It was previously shown that the gene has a protective role against tumor metastasis in the body, according to the university’s press release.

Advances in the care of patients with mucinous colorectal cancer

Mucinous colorectal cancer has, in the past, been associated with inferior responses to treatment, and worse patient outcomes compared with other colorectal cancer subtypes; although, this situation has improved in the past 10–15 years. In this Review, the authors describe the key developments that have enabled these improvements, in addition to the potential for further improvements in the care...

Researchers examine risk factors/patient outcomes associated with colorectal cancer

About 20 percent of colorectal cancer patients have cancers that have spread beyond the colon at the time of their diagnosis. In a new study, researchers provide a detailed comparison of patient outcomes associated with synchronous and sequential colorectal and liver resections in patients with stage IV colorectal cancer, identifying some benchmarks for surgical practice.

Gene thought to suppress cancer may actually promote spread of colorectal cancer

(University of Missouri-Columbia) A gene that is known to suppress the growth and spread of many types of cancer has the opposite effect in some forms of colorectal cancer, University of Missouri School of Medicine researchers have found. It is a finding that may lay the foundation for new colorectal cancer treatments.

Small molecule drug combined with chemotherapy may deliver a synergistic benefit for colorectal cancer patients

A study led by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has demonstrated the efficiency of a small molecule drug, PRIMA-1met, in inhibiting the growth of colorectal cancer cells. Colorectal cancer is the cancer of the large intestine (colon and rectum) and is the most common cancer in Singapore.

Using Bevacizumab in High-Risk Cervical Cancer

Dr Maurie Markman discusses a paper showing that bevacizumab significantly improves overall survival rates in high-risk cervical cancer patients. Medscape Oncology

Neoadjuvant Bevacizumab May Benefit Subset of Breast Cancer Patients

Preoperative bevacizumab may predominantly benefit breast cancer patients with a high baseline microvessel density, according to a new study.

The consensus molecular subtypes of colorectal cancer

An international consortium of colorectal cancer researchers undertakes a large-scale data sharing project to achieve a consensus molecular classification of colorectal cancers.

Colorectal and gastric cancer in 2015: The development of new agents and molecular classifications

In a little over the past year, several clinical trials have evaluated new drugs in patients with metastatic colorectal cancer and gastric cancer. Furthermore, genomics studies that attempted to unravel the molecular characteristics of colorectal and gastric cancer were published in 2015. The results of these endeavours will influence clinical practice in 2016 and beyond.

Research points to why some colorectal cancers recur after treatment

(University of Texas M. D. Anderson Cancer Center) Cetuximab, marketed as Erbitux, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients, shortening overall survival.

Researcher calls for changes to colorectal cancer screening guidelines

(University of Pennsylvania School of Medicine) Colorectal cancer will claim the lives of close to 50,000 Americans this year, according to the American Cancer Society. Screening is the most effective way to reduce the risk of dying from the disease, yet as a Penn Medicine physician argues in an editorial this week in the journal Gastroenterology, current recommendations to screen older people wit...

ECC 2015: Discovery of differences between tumours of younger and older colorectal cancer patients may lead to better treatments

Colorectal cancer (CRC) is on the rise among younger patients. Although some of the younger-onset cases can be explained by hereditary factors, the majority arise spontaneously. Researchers have now found that tumours in younger colorectal cancer...


Quick Search
Advertisement
 

News Quicklinks